EGFR and non-small cell lung carcinoma: Osimertinib formed irreversible covalent bonds with the cysteine 797 residue in the ATP-binding site, and it exhibited selective potency against the mutant EGFR rather than wild-type EGFR, resulting in its accelerated approval by US Food and Drug Administration to treat EGFR-mutated NSCLC [52].